Exhibit 99.1




DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results


- Company will host a business update conference call on September 25, 2018 at 4:30 PM Eastern Time -


VANCOUVER, British Columbia and MENLO PARK, California, September 24, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the year ended June 30, 2018. DelMar executive management will host a business update conference call for investors, analysts and other interested parties on September 25, 2018 at 4:30 p.m. Eastern Time.


“This past fiscal year has been an instrumental period for the Company on both corporate and clinical development fronts,” commented Saiid Zarrabian, President and Chief Executive Officer. “Moving forward, we are now a streamlined organization well positioned to advance VAL-083’s two Phase 2, biomarker-driven, clinical trials for MGMT-unmethylated GBM while evaluating combination therapies for this novel, first-in-class, DNA-targeting, small molecule, and in concert, ramping-up efforts to explore strategic opportunities to enhance shareholder value.”




Continued enrolling patients in Phase 2, open-label, second-line, Avastin-naïve, MGMT-unmethylated, recurrent glioblastoma multiforme (GBM) study being conducted at the MD Anderson Cancer Center (the “MDACC study”).


As of September 21, 2018, forty patients have been enrolled in the MDACC study, which continues accelerated enrollment rates observed since spring, 2018


The dosing levels used in the MDACC study have continued to demonstrate a safety profile well within the existing safety monitoring guidelines described in the present study protocol


Similar to prior clinical experience, myelosuppression has been the most common adverse event observed


Continued enrolling patients in Phase 2, open-label, first-line temozolomide-naïve, MGMT-unmethylated GBM study at Sun Yat-sen University Cancer Center.


As of September 21, 2018, nine patients have been enrolled in this study


Observed increased enrollment rates in the recent quarter







Engaged Oppenheimer & Co. Inc. as advisor to help manage the exploration and evaluation of a wide range of strategic opportunities


Strengthened Board of Directors and corporate governance by appointing world-renowned molecular biologist Dr. Napoleone Ferrara and Robert E. Hoffman as independent chairman


Appointed Saiid Zarrabian as full-time President and Chief Executive Officer


Based on overall clinical and corporate development progress achieved to date, expect to have cash available to fund planned operations into the middle of calendar 2019


For further details on the Company’s operating and financial results, as well as more detail about its updated strategy, refer to DelMar’s Form 10-K filed with the SEC on September 24, 2018: http://ir.delmarpharma.com/all-sec-filings.




DelMar will host a conference call to discuss its financial results for the year ended June 30, 2018 and provide a corporate update on September 25, 2018, at 4:30 p.m. Eastern Time. For both “listen-only” participants and those who wish to take part in the question and answer portion of the call, the telephone Dial-in Number is 1-877-876-9177 (toll free) with Conference ID DELMAR.


A replay of the conference call will be available on the IR Calendar of the Investors section of the Company’s website at www.delmarpharma.com and will be archived for 30 days.




At June 30, 2018, the Company had combined cash and cash equivalents and clinical trial deposits on hand of approximately $6.9 million.


For the year ended June 30, 2018, the Company reported a net loss of $11,138,312 or $0.54 per share, compared to a net loss of $8,081,764, or $0.74 per share, for the year ended June 30, 2017.


The following represents selected financial information as of June 30, 2018. The Company’s financial information has been prepared in accordance with U.S. GAAP and this selected information should be read in conjunction with DelMar’s consolidated financial statements and management’s discussion and analysis, as filed.


DelMar’s financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the company’s website at: http://ir.delmarpharma.com/all-sec-filings.







Selected Balance Sheet Data 



June 30,




June 30,



Cash and cash equivalents   5,971,995    6,586,014 
Working capital   5,407,929    6,566,371 
Total assets   7,074,855    7,911,021 
Derivative liability   1,117    61,228 
Total stockholders’ equity   5,435,223    6,578,524 


Selected Statement of Operations Data


For the years ended:


   June 30,   June 30, 
   2018   2017 
   $   $ 
Research and development   7,132,952    5,003,640 
General and administrative   4,041,711    3,317,189 
Change in fair value of stock option and derivative liabilities   (60,111)   (245,963)
Foreign exchange loss   57,003    7,355 
Interest income   (33,243)   (457)
Net and comprehensive loss for the period   11,138,312    8,081,764 
Series B preferred stock dividend   176,236    790,454 
Net and comprehensive loss available to common stockholders   11,314,548    8,872,218 
Basic weighted average number of shares outstanding   20,861,418    12,047,079 
Basic loss per share   0.54    0.74 


Research and development expenses increased to $7,132,952 during the year ended June 30, 2018, compared to $5,003,640 for the year ended June 30, 2017. The increase was partially due to manufacturing costs for drug product as well as ongoing study costs for the Company’s two Phase 2, biomarker-driven clinical studies. During the year ended June 30, 2018, the Company undertook site initiation and enrollment for its now parked STAR-3, Phase 3 study in GBM. During the year ended June 30, 2018, the Company recognized certain costs related to the parking of the trial.


General and administrative expenses increased in the year ended June 30, 2018 to $4,041,711 from $3,317,189 for the year ended June 30, 2017, largely due to an increase in professional fees and personnel costs.


About DelMar Pharmaceuticals, Inc.


DelMar is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options. By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments.







The Company’s current pipeline is based around VAL-083, a “first-in-class,” small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on DelMar’s internal research programs, and these prior NCI-sponsored clinical studies, the Company is conducting clinical trials to support the development and commercialization of VAL-083 to solve significant unmet medical needs.


VAL-083 is being studied in two collaborator-supported, biomarker-driven, Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM. In addition, DelMar has announced the allowance of a separate IND for VAL-083 as a potential treatment for platinum-resistant ovarian cancer.


Further information on DelMar’s clinical trials can be found on clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs


For additional information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989.


Connect with the Company on Twitter, LinkedIn, Facebook, and Google+.


Safe Harbor Statement


Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including, the Company’s Annual Report on Form 10-K for the year ended June 30, 2018, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.








The following information was filed by Delmar Pharmaceuticals, Inc. (DMPI) on Monday, September 24, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Delmar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Delmar Pharmaceuticals, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Log in with your credentials


Forgot your details?

Create Account